Everything below concerns GRF(1-29). We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-13. Numbers and descriptions here follow the published literature rather than marketing material.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
== History == The MHD description of electrically conducting fluids was first developed by Hannes Alfvén in a 1942 paper published in Nature titled "Existence of Electromagnetic–Hydrodynamic Waves", which outlined his discovery of what are now known as Alfvén waves. Alfvén initially referred to these waves as "electromagnetic–hydrodynamic waves"; however, in a later paper, he noted, "As the term 'electromagnetic–hydrodynamic waves' is somewhat complicated, it may be convenient to call this phenomenon 'magneto–hydrodynamic' waves."
== Wolf Prize == In 2006/07, he was awarded the Wolf Prize in Chemistry along with Ada Yonath of Weizmann Institute of Science in Rehovot, Israel for "ingenious structural discoveries of the ribosomal machinery of peptide-bond formation and the light-driven primary processes in photosynthesis".
== Products and services == Repligen develops and manufactures products used in bioprocessing and biological drug manufacturing. The company was a major supplier of Protein A, both native and recombinant forms, to the pharmaceutical industry, which accounted for most of its sales in the early 2010s. It has since expanded into other areas, including filtration and fluid management, chromatography, process analytics and proteins, serving biologics such as monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, fusion proteins, mRNA products, and cell and gene therapies. Some of its better-known product families include XCell ATF perfusion systems, OPUS pre-packed chromatography columns, KrosFlo tangential flow filtration systems, and CTech variable pathlength spectroscopy systems such as SoloVPE and FlowVPE. Many of these expansions have occurred through acquisitions, including BioFlash (OPUS), Refine Technology (ATF), ARTeSYN Biosolutions, and others. Growth factor products and the native form of Protein A and recombinant Protein A are manufactured in Sweden; assembly of the OPUS chromatography product line is done in the United States.
==== Siberia ==== In 1993, a team of Russian archaeologists led by Dr. Natalia Polosmak discovered the Siberian Ice Maiden, a Scytho-Siberian woman, on the Ukok Plateau in the Altai Mountains near the Mongolian border. The mummy was naturally frozen due to the severe climatic conditions of the Siberian steppe. Also known as Princess Ukok, the mummy was dressed in finely detailed clothing and wore an elaborate headdress and jewelry. Alongside her body were buried six decorated horses and a symbolic meal for her last journey. Her left arm and hand were tattooed with animal style figures, including a highly stylized deer. The Ice Maiden has been a source of some recent controversy. The mummy's skin has suffered some slight decay, and the tattoos have faded since the excavation. Some residents of the Altai Republic, formed after the breakup of the Soviet Union, have requested the return of the Ice Maiden, who is currently stored in Novosibirsk in Siberia. Another Siberian mummy, a man, was discovered much earlier in 1929. His skin was also marked with tattoos of two monsters resembling griffins, which decorated his chest, and three partially obliterated images which seem to represent two deer and a mountain goat on his left arm.
Sources: en.wikipedia.org
The Nobel Assembly at the Karolinska Institute did consider awarding half to Fleming and one-quarter each to Florey and Chain, but in the end decided to divide it equally three ways. On 25 October 1945, it announced that Fleming, Florey and Chain equally shared the 1945 Nobel Prize in Physiology or Medicine "for the discovery of penicillin and its curative effect in various infectious diseases." When The New York Times announced that "Fleming and Two Co-Workers" had won the prize, Fulton demanded – and received – a correction in an editorial the next day. Dorothy Hodgkin received the 1964 Nobel Prize in Chemistry "for her determinations by X-ray techniques of the structures of important biochemical substances", most notably penicillin and vitamin B12. She became only the third woman to receive the Nobel Prize in Chemistry, after Marie Curie in 1911 and Irène Joliot-Curie in 1935.
== Effects of digital agriculture adoption == The FAO estimates the world will need to produce 56% more food (as compared to 2010, under "business as usual" growth) to feed over 9 billion in 2050. Furthermore, the world faces intersecting challenges like malnutrition, climate change, food waste, and changing diets. To produce a "sustainable food future," the world must increase food production while cutting greenhouse gas emissions and maintaining (or reducing) the land used in agriculture. Digital agriculture can potentially address these challenges by making the agricultural value chain more efficient, equitable, and environmentally sustainable.
This basic structure was not touched by the Abbott, Turnbull and Morrison governments, although wages and standards continued to decline through lack of enforcement, growing casualization, and hostile judicial decisions. With the Albanese government, a series of reforms, such as the Fair Work Legislation Amendment (Closing Loopholes) Bill, aimed to raise protection, since Australian labour rights remained significantly below European and wealthier countries' standards. This includes the lack of a restored system for sectoral collective bargaining, weak protection for collective action, and absence of rights for workers to elect directors on boards of enterprises, outside isolated examples in universities or the Australian Broadcasting Corporation, 25 per cent of people on "casual" contracts, and stagnating real wages.
== See also == Other diamond-like compounds: Boron nitride Abiogenic petroleum origin Nanorobot “Diamonoids” were claimed as an airburst proxy, but may have been a misspelling of diamondoid in a now-retracted paper.
coenocyte A multinucleate mass of cytoplasm bounded by a cell wall and resulting from continuous cytoplasmic growth and repeated nuclear division without cytokinesis, found in some species of algae and fungi, e.g. Vaucheria and Physarum.
Sources: en.wikipedia.org
According to the Encyclopedia Britannica, "the attempt by Salvador Allende to unite Marxists and other reformers in a socialist reconstruction of Chile is most representative of the direction that Latin American socialists have taken since the late 20th century. ... Several socialist (or socialist-leaning) leaders have followed Allende's example in winning election to office in Latin American countries." Venezuelan President Hugo Chávez, Nicaraguan President Daniel Ortega, Bolivian President Evo Morales and Ecuadorian President Rafael Correa refer to their political programmes as socialist and Chávez adopted the term socialism of the 21st century. After winning re-election in December 2006, Chávez stated: "Now more than ever, I am obliged to move Venezuela's path towards socialism." The pink tide is a term used in the 2000s in political analysis in the media and elsewhere to describe the perception that left-wing politics were becoming increasingly influential in Latin America. To network this movement, the Foro de São Paulo is a conference of leftist political parties and other organisations from Latin America and the Caribbean.
Pharmacology has become increasingly sophisticated; modern biotechnology allows drugs targeted towards specific physiological processes to be developed, sometimes designed for compatibility with the body to reduce side-effects. Genomics and knowledge of human genetics and human evolution is having increasingly significant influence on medicine, as the causative genes of most monogenic genetic disorders have now been identified, and the development of techniques in molecular biology, evolution, and genetics are influencing medical technology, practice and decision-making. Evidence-based medicine is a contemporary movement to establish the most effective algorithms of practice (ways of doing things) through the use of systematic reviews and meta-analysis. The movement is facilitated by modern global information science, which allows as much of the available evidence as possible to be collected and analyzed according to standard protocols that are then disseminated to healthcare providers. The Cochrane Collaboration leads this movement. A 2001 review of 160 Cochrane systematic reviews revealed that, according to two readers, 21.3% of the reviews concluded insufficient evidence, 20% concluded evidence of no effect, and 22.5% concluded positive effect.
In 2007, videos were shared on YouTube of alleged salvia users laughing uncontrollably, apparently unable to perform simple tasks or to communicate. In an interview published in the San Francisco Chronicle in June 2007, Daniel Siebert said that the videos "make salvia look like some horrible drug that makes people nuts and dangerous ..." and that it stops people from realizing "there are sensible ways to use something like this." Waco Representative Charles Anderson (R), who is sponsoring one of several bills to ban salvia in Texas, told colleagues at a legislative hearing about a video that depicts a salvia user behind the wheel of a car. "What we really worry about, is youngsters doing this and then getting in a vehicle or getting on a motorcycle or jumping in a pool somewhere." Michigan Representative Michael Sak (D) submitted a bill which proposed Schedule I classification of Salvia divinorum and salvinorin A. He said that if people had questions about the deleterious effects of salvia, they should go on YouTube to watch the videos. A reporter questioned Sak as to whether he had ever seen a "Girls Gone Wild" video, and whether that would incite him to make alcohol illegal (Sak replied that he hadn't yet had a chance to review the material).
==== Multifunctional alginate scaffolds ==== Multifunctional alginate scaffolds for T cell engineering and release (MASTER) is a technique for in situ engineering, replication and release of genetically engineered T cells. It is an evolution of CAR T cell therapy. T cells are extracted from the patient and mixed with a genetically engineered virus that contains a cancer-targeting gene (as with CAR T). The mixture is then added to a MASTER (scaffold), which absorbs them. The MASTER contains antibodies that activate the T cells and interleukins that trigger cell proliferation. The MASTER is then implanted into the patient. The activated T cells interact with the viruses to become CAR T cells. The interleukins stimulate these CAR T cells to proliferate, and the CAR T cells exit the MASTER to attack the cancer. The technique takes hours instead of weeks. And because the cells are younger, they last longer in the body, show stronger potency against cancer, and display fewer markers of exhaustion. These features were demonstrated in mouse models. The treatment was more effective and longer-lasting against lymphoma.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.